Silvant Capital Management LLC bought a new stake in Becton Dickinson (NYSE:BDX) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 30,501 shares of the medical instruments supplier’s stock, valued at approximately $6,609,000.
Several other hedge funds have also bought and sold shares of BDX. Renaissance Technologies LLC lifted its position in Becton Dickinson by 1,192.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,074,503 shares of the medical instruments supplier’s stock worth $444,068,000 after buying an additional 1,913,952 shares during the last quarter. BlackRock Inc. lifted its position in Becton Dickinson by 6.0% in the fourth quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after buying an additional 1,071,288 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its position in Becton Dickinson by 332.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 559,551 shares of the medical instruments supplier’s stock worth $119,776,000 after buying an additional 430,127 shares during the last quarter. Gardner Lewis Asset Management L P bought a new stake in Becton Dickinson in the fourth quarter worth $63,668,000. Finally, HBK Investments L P bought a new stake in Becton Dickinson in the fourth quarter worth $61,551,000. 84.02% of the stock is owned by hedge funds and other institutional investors.
NYSE:BDX opened at $224.22 on Friday. Becton Dickinson has a twelve month low of $223.76 and a twelve month high of $224.74. The firm has a market cap of $60.09 billion, a PE ratio of 22.51, a price-to-earnings-growth ratio of 1.56 and a beta of 1.15. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Investors of record on Friday, June 8th will be issued a $0.75 dividend. The ex-dividend date is Thursday, June 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.34%. Becton Dickinson’s payout ratio is currently 31.65%.
A number of analysts recently issued reports on BDX shares. Citigroup upgraded Becton Dickinson from a “neutral” rating to a “buy” rating and raised their price target for the stock from $237.00 to $251.00 in a research report on Tuesday, April 10th. Bank of America restated a “buy” rating and issued a $260.00 price target on shares of Becton Dickinson in a research report on Friday, January 19th. Zacks Investment Research upgraded Becton Dickinson from a “hold” rating to a “buy” rating and set a $259.00 target price for the company in a research report on Friday, January 19th. BMO Capital Markets started coverage on Becton Dickinson in a research report on Monday, March 5th. They set a “market perform” rating and a $249.00 target price for the company. Finally, Morgan Stanley lifted their target price on Becton Dickinson from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson has a consensus rating of “Buy” and a consensus price target of $241.19.
In related news, EVP Nabil Shabshab sold 10,209 shares of Becton Dickinson stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $226.10, for a total value of $2,308,254.90. Following the completion of the sale, the executive vice president now directly owns 12,476 shares in the company, valued at $2,820,823.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy M. Ring sold 176 shares of Becton Dickinson stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the completion of the sale, the director now owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The disclosure for this sale can be found here. Insiders sold 21,656 shares of company stock valued at $4,892,092 over the last 90 days. 1.00% of the stock is currently owned by corporate insiders.
Becton Dickinson Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.